Evidence map›Paper›PMID 38167126›Full record

ArticleCancer cell international2024

LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p/SPP1 axis as a ceRNA.

Liu Ouyang, Min-Min Sun, Ping-Sheng Zhou, Yi-Wei Ren, Xin-Yu Liu, Wan-Ying Wei, Zhen-Shun Song, Kai Lu, Li-Xue Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Liu Ouyang *Department of Hepatobiliary and Pancreatic (HBP) Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
Min-Min Sun *Department of Hepatic Surgery I, The Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China.
Ping-Sheng Zhou *Department of Ultrasonic Intervention, The Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China.
Yi-Wei RenDepartment of Hepatobiliary and Pancreatic (HBP) Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
Xin-Yu LiuDepartment of Hepatobiliary and Pancreatic (HBP) Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Wan-Ying WeiDepartment of Biliary Tract Surgery II, The Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China.
Zhen-Shun SongDepartment of Hepatobiliary and Pancreatic (HBP) Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China. songsurery1@163.com.
Kai LuDepartment of Biliary Tract Surgery II, The Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China. lukaiehbh@163.com.
Li-Xue YangDepartment of Biliary Tract Surgery II, The Third Affiliated Hospital of Naval Medical University, Shanghai, 200438, China. ylx899@aliyun.com.
Second Military Medical University · CNChanghai Hospital · CNThe Third Affiliated Hospital of Zhejiang Chinese Medical University · CNThird Affiliated Hospital of Southern Medical University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) play a pivotal role in the pathogenesis of human cancers. Previous studies have highlighted the role of long non-coding RNA (lncRNA) in modulating the stemness of CSCs. In our investigation, we identified an upregulation of lncRNA FOXD1-AS1 in CSCs. The enforced expression of lncRNA FOXD1-AS1 promotes tumorigenesis and self-renewal in pancreatic cancer CSCs. Conversely, the knockdown of lncRNA FOXD1-AS1 inhibits tumorigenesis and self-renewal in pancreatic cancer CSCs. Furthermore, our findings reveal that lncRNA FOXD1-AS1 enhances self-renewal and tumorigenesis in pancreatic cancer CSCs by up-regulating osteopontin/secreted phosphoprotein 1(SPP1) and acting as a ceRNA to sponge miR-570-3p in pancreatic cancer (PC) CSCs. Additionally, lncRNA FOXD1-AS1 depleted pancreatic cancer cells exhibit heightened sensitivity to 5-FU-indued cell growth inhibition and apoptosis. Analysis of patient-derived xenografts (PDX) indicates that a low level of lncRNA FOXD1-AS1 may serve as a predictor of 5-FU benefits in PC patients. Moreover, the introduction of SPP1 can reverse the sensitivity of lncRNA FOXD1-AS1-knockdown PC cells to 5-FU-induced cell apoptosis. Importantly, molecular studies have indicated that the elevated levels of lncRNAFOXD1-AS1 in PC are facilitated through METTL3 and YTHDF1-dependent m

Indexed as

Cancer stem celllncRNA FOXD1-AS1N6-methyladenosine, 5-FUPancreatic cancer

Identifiers

PMID38167126
PMCPMC10763109
OpenAlexW4390496524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.